All posts by Clay Wilemon

May 18 Event_Blog-cropped

200 People Attend “Communicating Value” Event

Articles, Press

On May 18, 2017, DevicePharm and Medical Alley Association co-sponsored an event titled “Communicating Value – Marketing Success In A Value-Driven Environment”. The event, held in the iconic Guthrie Theater in downtown Minneapolis, was attended by 200 members of the Minnesota medical device, biotech, diagnostics, and pharmaceutical community.

Read More
Austin office v2

DevicePharm Opens Austin, TX Office

Articles

On May 1, 2017, DevicePharm announced the opening of our new office in Austin, Texas. This office was developed to serve the growing medical technology industry in Austin, Houston, Dallas, and San Antonio.

Clay Wilemon, DevicePharm CEO and Chief Strategy Officer described the motivation for opening the Austin office, “Texas has over 700 medical device, biotech, diagnostics, and pharmaceutical companies.

Read More
micro-invasive

Sonex Health Completes First Surgery for Micro-Invasive Treatment of Carpal Tunnel Syndrome

Medical Device Marketing, Press

On February 22, 2017, Sonex Health announced the successful completion of the first ultrasound-guided carpal tunnel release procedure in the United States using the SX-One MicroKnife™. The SX-One MicroKnife™ is an ultra-low profile surgical device that allows physicians to perform Micro-invasive carpal tunnel release (CTR) surgery through a single micro-incision (4-5 mm) using ultrasound guidance.

Read More
7D Surgical

7D Surgical Announces Regulatory Milestones

Medical Device Marketing, Press Release

7D Surgical announced today that it has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada enabling the North American commercial launch of its innovative Machine-vision Image Guided Surgery (MIGS™) system for spine surgery, the 7D Surgical System. This breakthrough system is designed to simplify and speed up surgical workflow, increase surgeon control, eliminate intraoperative radiation, and deliver exceptional value.

Read More
Agendia

46% Of High Risk Breast Cancer Patients May Not Require Chemo

Articles, Case Studies

Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.

Read More